Genmab A/S ADR (GMAB) Social Stream
GENMAB A (GMAB) Price Targets From Analysts
Use the tables below to see what analysts covering GENMAB A think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-11 | 6 | $50 | $37 | $44.8 | $38.53 | 16.27% |
| 2021-11-15 | 7 | $50 | $37 | $44.7 | $38.53 | 16.01% |
| 2022-01-18 | 8 | $50 | $37 | $44.7 | $38.53 | 16.01% |
| 2022-01-31 | 8 | $50 | $37 | $44.7 | $38.53 | 16.01% |
| 2022-02-28 | 8 | $50 | $37 | $42.2 | $38.53 | 9.53% |
| 2022-04-07 | 8 | $50 | $33 | $41.4 | $38.53 | 7.45% |
| 2022-04-11 | 9 | $50 | $33 | $41.416 | $38.53 | 7.49% |
| 2022-04-21 | 9 | $50 | $30 | $40.916 | $38.53 | 6.19% |
| 2022-05-02 | 10 | $50 | $30 | $40.5 | $38.53 | 5.11% |
| 2022-05-12 | 10 | $50 | $30 | $38.571 | $38.53 | 0.11% |
| 2022-05-13 | 10 | $50 | $30 | $37.9 | $38.53 | -1.64% |
| 2022-06-05 | 10 | $50 | $29 | $37.757 | $38.53 | -2.01% |
| 2022-07-20 | 11 | $53 | $29 | $38.003 | $38.53 | -1.37% |
| 2022-08-13 | 11 | $53 | $29 | $38.441 | $38.53 | -0.23% |
| 2022-08-15 | 11 | $53 | $31 | $38.691 | $38.53 | 0.42% |
| 2022-08-25 | 11 | $53 | $31 | $38.941 | $38.53 | 1.07% |
| 2022-10-19 | 11 | $53 | $31 | $39.316 | $38.53 | 2.04% |
| 2022-11-10 | 12 | $53 | $31 | $39.753 | $38.53 | 3.17% |
| 2022-11-14 | 12 | $53 | $33 | $40.128 | $38.53 | 4.15% |
| 2022-12-03 | 13 | $53 | $33 | $40.753 | $38.53 | 5.77% |
| 2023-01-03 | 13 | $53 | $33 | $42.091 | $38.53 | 9.24% |
| 2023-01-26 | 13 | $53 | $33 | $42.653 | $38.53 | 10.7% |
The Trend in the Analyst Price Target
GMAB's average price target has moved up $1.25 over the prior 42 weeks.
Over the past 51 weeks, GMAB's average upside potential has been 8.51%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-02-28 | 8 | 50 | 37 | 42.200 | 33.46 | 26.12% |
| 2022-04-21 | 9 | 50 | 30 | 40.916 | 37.48 | 9.17% |
| 2022-05-18 | 10 | 50 | 29 | 37.757 | 29.59 | 27.6% |
| 2022-09-17 | 11 | 53 | 31 | 39.316 | 36.46 | 7.83% |
| 2022-11-14 | 12 | 53 | 33 | 40.128 | 42.54 | -5.67% |
GMAB Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.59 | 4 | 0 | 7 | 1 | 1 | 13 |
The Trend in the Broker Recommendations
Over the past 36 months, GMAB's average broker recommendation rating worsened by 0.87.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- GMAB has a higher upside potential (average analyst target price relative to current price) than 553.02% of all US stocks.
- GENMAB A's average analyst price target is greater than 586.84% of stocks in the large market cap category.
- In the context of Pharmaceutical Products stocks, GENMAB A's number of analysts covering the stock is higher than 1930.58% of them.
- GMAB has a lower variance in analysts' estimates than -752.23% of Pharmaceutical Products stocks.
In the Pharmaceutical Products industry, ELAN, ZLAB, and RDY are the three stocks most similar to GENMAB A regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Is GMAB a Buy, Hold or Sell? See the POWR Ratings now!